Stoke Therapeutics Presents New In-Vivo Data That Demonstrat

– Data presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting support the Company’s work to advance STK-002 as the first potential disease modifying treatment for Autosomal Dominant Optic Atrophy (ADOA) –– ADOA is the most common inherited optic nerve disorder –BEDFORD, Mass.--(B...

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Denmark , Bedford , Massachusetts , United States , Edwardm Kaye , Eric Rojas , Karen Anderson , Augmentation Of Nuclear Gene Output , Stoke Therapeutics Inc , Nasdaq , Company Annual Report On Form , Exchange Commission , Ophthalmology Program , Association For Research , Protein Expression After Intravitreal Administration To Primates , Annual Meeting , Autosomal Dominant Optic Atrophy , Stoke Therapeutics , Chief Executive Officer , Antisense Oligonucleotide , Retinal Ganglion Cells , Expression After Intravitreal Administration , Non Human Primates , Ophthalmology Program Lead , Targeted Augmentation , Nuclear Gene Output , Antisense Oligonucleotides , Associate Principal Scientist , Private Securities Litigation Reform Act , Annual Report , Investor Contacts , Investor Relations ,